From: [redacted]
To: [redacted]
Cc: [redacted]
Subject: Celestone Chronodose ADR report due to possible product contamination [SEC=UNCLASSIFIED]
Date: Monday, 11 July 2016 5:50:47 PM

Dear [redacted]

I refer to the adverse event report of fungal joint infection following Celestone Chronodose intra-articular injection (ADR 386482, your reference AUS/16/0843) submitted to the TGA on the 19th of April 2016. Please be aware that the TGA has recently received a second report of fungal joint infection with *S. prolificans* after intra-articular injection with Celestone Chronodose in a different patient.

We are investigating further and will be in touch if we require any information.

Kind regards,

[redacted]
Medical Officer
Adverse Event Monitoring and Vaccine Safety
Pharmacovigilance and Special Access Branch

Phone: [redacted]
Email: [redacted]

Therapeutic Goods Administration
Department of Health
PO Box 100
Woden ACT 2606 Australia
www.tga.gov.au